Pharma fundings, SPACs and our other VC predictions for 2021
December 14, 2020
After 2020 turned into a year nobody saw coming, trying to predict what will unfold in the next 12 months of VC dealmaking might seem like an ambitious errand. Luckily, it's one for which our analyst team is well equipped.
The rollout of vaccines and the future of the pandemic will have obvious influence on what's to come. So too will the presence of a new administration in the White House, with the potential for major changes to policies on taxes, immigration and trade. What will it all mean? Here are a few of our best guesses for what's ahead in 2021:
The rollout of vaccines and the future of the pandemic will have obvious influence on what's to come. So too will the presence of a new administration in the White House, with the potential for major changes to policies on taxes, immigration and trade. What will it all mean? Here are a few of our best guesses for what's ahead in 2021:
- After a record-breaking 2020, biotech and pharma VC deal activity will again top $20 billion
- Fewer than 30% of the SPACs that went public in 2020 will close an acquisition in 2021
- The Bay Area will fall below a 20% share of US deal count for the first time